A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
NCT07428616
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Meningioma
Interventions
DRUG:
Zanzalintinib
Sponsor
Exelixis